Stocks to invest in – Wondering What’s Happening in the Financial Markets Today? Check Out These Stories!



Stocks to invest in

1. U.S. Stock Market:

 

“U.S. equities traded mixed on Tuesday as investors digested key economic data, while tech stocks continued to rally. The Nasdaq composite rose 0.1 percent as shares of Amazon broke above $1,000 for the first time. The S&P 500 slipped 0.1 percent, with energy leading decliners, but a slight gain in the information technology helped cap losses. Tech has been on fire this year, rising nearly 20 percent. The Dow Jones industrial average fell 25 points, with Chevron contributing the most losses. U.S. stock markets were closed Monday because of the Memorial Day holiday.”

(CNBC)

“U.S. stocks opened slightly lower on Tuesday after a three-day holiday weekend as oil prices fell and investors parsed a barrage of economic data for a reading on the health of the economy. At 9:36 a.m. ET (1336 GMT), the Dow Jones Industrial Average was down 26.65 points, or 0.13 percent, at 21,053.63, the S&P 500 was down 3.27 points, or 0.13 percent, at 2,412.55. The Nasdaq Composite was up 2.33 points, or 0.04 percent, at 6,212.53.”


(Reuters)

“U.S. stocks pulled back from record levels on Tuesday, with energy shares leading the day’s decline even though the market’s uptrend was seen as remaining intact following a multisession rally. The Dow Jones Industrial Average DJIA, -0.18% fell 54 points, or 0.3%, to 21,025. The S&P 500 SPX, -0.10% slid 5 points to 2,411, a decline of 0.2%. The Nasdaq Composite Index COMP, -0.03% lost 4 points to 6,206, a loss of less than 0.1%.”

(Market Watch)

stocks-to-invest-in

Bloomua/Shutterstock.com

 

2. U.S. Bond Market:

 

“The U.S. Treasuries gained ahead of the Federal Open Market Committee (FOMC) member Brainard’s speech, due to be held later today and Kaplan’s speech, scheduled for May 31. The yield on the benchmark 10-year Treasury, slipped 1 basis point to 2.24 percent, the super-long 30-year bond yields also fell 1 basis point to 2.90 percent and the yield on short-term 2-year note traded tad 1/2 basis point lower at 1.29 percent.”

(EconoTimes)

“The benchmark 10-year note yield began 2017 trading near 2.5 percent but hovered near 2.23 percent on Tuesday.”

(CNBC)

 

3. FX Markets:

“The euro pulled back from the day’s lows against the dollar and the yen on Tuesday, after weakening broadly earlier as European geopolitical fears sapped risk appetite. EUR/USD was at 1.1163 by 06.22 ET, after falling as low as 1.1108 earlier. EUR/JPY was last at 123.92, still off 0.24% for the day after falling to 123.16 earlier, the lowest level since May 18. The dollar was also weaker against the safe haven yen, with USD/JPY down 0.22% at 111.01. Sterling pushed higher, with GBP/USD rising 0.15% to 1.2859, but gains were held in check as the election race in the UK tightened, adding to political risk around Brexit. The pound was also higher against the euro, with EUR/GBP down 0.22% at 0.8677.”

(Investing.com)

“Political worries over Greece, Italy and Britain had European currencies on the retreat against the dollar on Tuesday, with a bleaker mood on stock markets also pushing the yen higher. The dollar index, under pressure over the past fortnight from concerns over the Trump administration’s difficulties, gained around 0.1 percent in morning trade in Europe. Other major markets were also deeply in the red, with French shares sinking almost 1 percent .FCHI, prodding investors toward the traditional security of the yen, which gained around 0.3 percent against the dollar JPY= and 0.4 percent against the euro. Sterling recovered from some early losses to trade 0.2 percent higher at $1.2868.”

(Reuters)

4. Commodities:

 

“Lingering disappointment over last week’s OPEC decision to keep production cuts stable and lingering supply-side strains pushed oil prices lower early Tuesday. The price for Brent crude oil was down 1.4 percent about 15 minutes before the start of trading in New York to $51.41 per barrel. West Texas Intermediate, the U.S. benchmark price for oil, was down 0.92 percent to $49.35 per barrel.”

(UPI.com)

 

“The gold market remains under pressure but off its lowest, following a larger-than-expected drop in U.S. consumer confidence. Tuesday, the U.S. Conference Board, reported that its consumer confidence index fell to a reading of 117.9 in May, down from April’s revised reading of 119.4. Economists were expecting to see relatively unchanged consumer sentiment, with consensus forecasts calling for a reading around 113.9. The Gold market has been attracting some modest technical profit taking after hitting a one-month high overnight. While the yellow metal is off its lows, initial reaction still shows some weakness in the marketplace; August Comex gold futures last traded at $1,266 an ounce, down 0.42% on the day.”

(Kitco News)

 

5. Market Movers:

 

Amazon.com, Inc. (NASDAQ:AMZN)‘s shares topped $1,000 for the first time, marking a new milestone for a company wooing investors by dominating online commerce and cloud computing. Amazon shares hit $1,001.20 in New York Tuesday, up about 40 percent from a year ago and more than double the 15 percent gain of the S&P 500 Index in the same period. Investors are thinking about how much further Amazon can grow as it tries to replicate its U.S. success abroad.

(Bloomberg)

Follow Amazon Com Inc (NASDAQ:AMZN)

Trade (NASDAQ:AMZN) Now!

Xactly Corp (NYSE:XTLY) announced Tuesday morning that it has entered into a definitive agreement to be acquired by Vista Equity Partners for approximately $564 million. Xactly stockholders will receive $15.65 in cash per share. Xactly has gapped open sharply higher Tuesday and is now up 2.13 at $15.53 with volume at over a 5-month high. The stock is now challenging the highs of the year, trading at nearly a 9-month high.

(RTT News)

Follow Xactly Corp (NYSE:XTLY)

Trade (NYSE:XTLY) Now!

GlaxoSmithKline plc (ADR) (NYSE:GSK) shares outperformed the market Tuesday after clinical trials data for Gilead Sciences, Inc. (NASDAQ:GILD)‘s Bictegravir HIV treatment appeared to reduce the threat of a superior rival to GSK’s Dolutegravir. Gilead said Tuesday that Bictegravir met its end point of non-inferiority in four separate phase III clinical trials, when combined with emtricitabine, as a treatment for HIV-1. The U.S. drug maker has been running its Bictegravir treatment head to head as a combo with Glaxo’s Dolutegravir in trials and has said it aims to file for approval with the Food & Drug Administration in the current quarter.

(TheStreet)

Follow Glaxosmithkline Plc (NYSE:GSK)

Trade (NYSE:GSK) Now!

Shares of TiVo Corp (NASDAQ:TIVO) TIVO, +8.69% were up more than 10% early on Tuesday after winning a patent case against Comcast Corp. CMCSA, +1.49% The administrative law judge in TiVo’s International Trade Commission case issued an initial ruling regarding two of TiVo’s patents relating to set-top boxes, finding that Comcast had violated section 337, which involves imports. A final ruling is expected Sept. 26. following a full investigation into the infringement. If the ruling doesn’t change after that, certain Comcast set-top boxes that infringe on the patent could be blocked at the port, according to Cowen analyst Robert Stone.

(Market Watch)

Follow Tivo Corp

Trade (TIVO) Now!

Shares of Array Biopharma Inc (NASDAQ:ARRY) jumped 6.6% to $8.70 in premarket trading on Tuesday. The Boulder, Colo.-based firm and Bristol-Myers Squibb Co (NYSE:BMY) announced a research collaboration that takes a look at Array’s investigational MEK inhibitor, binimetinib, in tandem with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients that have microsatellite stable tumors.

(TheStreet)

Follow Array Biopharma Inc (NASDAQ:ARRY)

Trade (NASDAQ:ARRY) Now!

Protagonist Therapeutics Inc (NASDAQ:PTGX) saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing and collaboration agreement with Janssen Biotech, a subsidiary of Johnson & Johnson (NYSE: JNJ). The agreement actually builds on a Johnson & Johnson Innovation — JJDC Inc. Series B venture financing from 2013 in support of the discovery and development of Protagonist’s pipeline of oral peptide therapeutics.

(247WallSt.com)

Follow Protagonist Therapeutics Inc

Trade (PTGX) Now!

Shares of Zynga Inc (NASDAQ:ZNGA) ZNGA, +2.58% climbed 2.3% in premarket trade Tuesday after the stock was upgraded to overweight from neutral at Piper Jaffray. Though the analysts still see mobile games companies as high risk, they say Zynga’s attention to live services and the company’s focus on cost containment, meaning maintaining existing games, rather than depending on producing new “mega-hits,” lower the risk of the investment.

(Market Watch)

Follow Zynga Inc (NASDAQ:ZNGA)

Trade (NASDAQ:ZNGA) Now!

– Stocks to invest in

Learn How To Be #1 on Google Results



Source link